The Paula and Rodger Riney Foundation partnered with International Myeloma Society to further their mutual goals of supporting cutting-edge translational research and further careers of young basic and clinical researchers in myeloma. The goals of the Foundation and the society has been to promote interdisciplinary collaborations among colleagues at major centers building a bridge between basic science and clinical care, with the ultimate goal to accelerate new strategies and innovative approaches to improve patient outcomes.
To assist in the critical effort to help develop the next generation of researchers, the Foundation along with the International Myeloma Society has established a Career Development Award for young investigators, and issued several grants for scientists focused on translational research in the field of plasma cell dyscrasias.
Rodger O. Riney is the founder of Scottrade, a multi-billion-dollar retail and online stockbroker company he sold to TD Ameritrade in 2017, two years after being diagnosed with multiple myeloma. After the sale of Scottrade, Rodger and his wife, Paula, founded the Paula and Rodger Riney Foundation to fund scientific research leading to a better understanding and possible cure for multiple myeloma and related cancers.
Since its creation, the Foundation has donated millions of dollars to leading medical and research institutions around the globe to establish centers, initiatives, programs and funds focused on the development, testing and approval of more effective and less toxic novel therapies for multiple myeloma and other plasma cell disorders.
It is the Rineys’ sincere hope that, with the Foundation’s support, the scientific community’s collective research and knowledge can, and will, lead to a cure for, what up until now, has been an incurable disease.
The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide. The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.